重组人血管内皮抑制素联合腔内化疗治疗恶性胸腹水的临床观察  

Clinical observation of the efficacy of intracavitary injection of endostar combined with chemotherapy on malignant pleural effusion and ascites

作　　者：袁昕[1] 童建东[1] 汪竹[1] 殷旭东[1] 韩芳[1] 

机构地区：[1]扬州市第一人民医院肿瘤科,江苏扬州225000

出　　处：《临床肿瘤学杂志》2011年第2期165-167,共3页Chinese Clinical Oncology

摘　　要：目的观察重组人血管内皮抑制素(恩度)联合腔内化疗治疗恶性胸腹水患者的疗效和安全性。方法 80例恶性胸腹水患者分为腔内恩度联合化疗组(治疗组)和腔内化疗组(对照组)。治疗前均先排尽胸腹水,治疗组在胸腔内注入顺铂(DDP)60mg和恩度60mg,在腹腔内注入DDP 60mg、氟尿嘧啶(5-FU)1.0g和恩度60mg。对照组除不加入恩度外,其余同治疗组。结果在可评价的76例患者中,治疗组总有效率为79.1%,对照组57.6%,其中治疗组恶性胸水患者的有效率为88.9%,恶性腹水患者为72.0%;对照组恶性胸水患者的有效率为60.0%,恶性腹水患者为55.6%,两组疗效差异显著(P<0.05)。全组患者耐受良好,无严重不良反应。治疗组中位生存期为5.8个月,略长于对照组的4.6个月,但两组差异无统计学意义(P>0.05)。结论腔内恩度联合化疗治疗恶性胸腹水有效且安全。Objective To study the efficacy and safety of intracavitary injection of endostar combined with chemotherapy of malignant pleural effusion and ascites.Methods Eighty cases of the patients with malignant pleural effusion and ascites were divided into groups of intracavitary injection of endostar combined with chemotherapy of malignant pleural effusion and ascites（treatment group）and groups of intracavitary chemotherapy（control group）.Pleural effusion and ascites of the patients from the two groups were both exhausted first.Patients of the treatment group suffering from pleural effusion were injected cisplatin（DDP） 60mg into the thorax and 60mg of endostar.To the patients of treatment group suffering from ascites,artificial ascites was formed first,and then DDP 60mg,fluorouracil（5-FU） 1.0g as well as 60mg of endostar was injected into abdomen.The same therapy applied to the control group except adding endostar.Results Among the evaluable 76 cases,the total effective rate of the treatment group was 79.1%,while 57.6% of the control group.The effective percentage of malignant pleural effusion treatment group was 88.9% among the cases,while 60.0% of the control group.As for the malignant ascites treatment group it was 72.0%,while 55.6% of the control group.All the patients were of good tolerance as a whole and no severe side effects happened.The median survival time of the treatment group and control group was 5.8 months and 4.6 months（P〉0.05）.Conclusion The therapy of intracavitary injection of endostar combined with chemotherapy of malignant pleural effusion and ascites is effective and secure.

关 键 词：重组人血管内皮抑制素 恶性胸腹水 腔内化疗 

分 类 号：R730.5[医药卫生—肿瘤]